Steve Hall
Amministratore Delegato presso Esanex, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| S. Torres | M | 61 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | 22 anni |
| Bruce Jacobs | M | 54 | 5 anni | |
| Pamela Esposito | M | 50 | 4 anni | |
| Gorjan Hrustanovic | M | 35 | 4 anni | |
| Joanna Horobin | M | 69 | 6 anni | |
| John Maraganore | M | 60 | 2 anni | |
| Marcel Frenkel | M | - |
TEN63 Therapeutics
 TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | 4 anni |
| Mark Hallen | M | - |
TEN63 Therapeutics
TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | 4 anni |
| Elena Ridloff | F | 44 | 3 anni | |
| Jeannette Potts | M | 62 | 5 anni | |
| Brian Albarran | M | - | 6 anni | |
| Bruce Donald | M | - |
TEN63 Therapeutics
TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | 4 anni |
| Jeffrey Albers | M | 52 | 4 anni | |
| Richard J. Cohen | M | 73 |
Massachusetts Institute of Technology
| 45 anni |
| Juliet Williams | M | - | 3 anni | |
| Kevin Dushney | M | - | 3 anni | |
| Ashwin Gollerkeri | M | - | 3 anni | |
| Karen Weisbach | F | - | 3 anni | |
| Julie Gilmore | M | - |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | - |
| Melissa Brody | F | - | 3 anni | |
| Jared Gollob | M | 60 | 6 anni | |
| Fiorella Kostoris | F | 79 |
Massachusetts Institute of Technology
| 44 anni |
| Vijay Sabesan | M | 51 | 3 anni | |
| Damien Petty | M | - |
TEN63 Therapeutics
TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | 3 anni |
| David N. Cook | M | 66 | 4 anni | |
| Nag Rayapureddi | M | - |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | 12 anni |
| Todd Shegog | M | 59 | 5 anni | |
| John B. Mitchell | M | 72 |
Central Michigan University
| 49 anni |
| Mary Wadlinger | F | 64 | 10 anni | |
| Richard J. Miller | M | 62 |
Esanex, Inc.
 Esanex, Inc. Pharmaceuticals: MajorHealth Technology Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN. | - |
| Rick S. Kent | M | 74 |
Esanex, Inc.
Esanex, Inc. Pharmaceuticals: MajorHealth Technology Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN. | - |
| Alexander M. Klibanov | M | 74 |
Massachusetts Institute of Technology
| 45 anni |
| John F. Rockart | M | 92 |
Massachusetts Institute of Technology
| 42 anni |
| Aimee Mishkin | F | - | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Christopher Guiffre | M | 56 |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| William Rastetter | M | 75 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA.
Massachusetts Institute of Technology
| 11 anni |
| Paul Friedman | M | 81 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 anni |
| Ram Sasisekharan | M | 58 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 anni |
| Oliver Fetzer | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 anni |
| Michael A. Foley | M | 62 | 9 anni | |
| Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 anni |
| Mark A. Clements | M | - |
Massachusetts Institute of Technology
| 3 anni |
| Laurent Audoly | M | - | - | |
| Frank Lee | M | 56 | 3 anni | |
| Steven C. Webster | M | 67 |
Massachusetts Institute of Technology
| 5 anni |
| On-kwok Li | M | 69 |
Massachusetts Institute of Technology
| 3 anni |
| Barbara Poggiali | M | 61 |
Massachusetts Institute of Technology
| 5 anni |
| Andrew Hedin | M | 39 | 3 anni | |
| Susan Kelley | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 anni |
| Camilo Gomez | M | - |
Massachusetts Institute of Technology
| 8 anni |
| Anil Bhaskar Chaudhary | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Paolo Augusto Paoletti | M | 73 | 6 anni | |
| Sahba S. Vaziri | F | - |
Massachusetts Institute of Technology
| 6 anni |
| Mark Gus Alexandridis | M | 66 |
Massachusetts Institute of Technology
| 6 anni |
| Tom Leighton | M | 67 |
Massachusetts Institute of Technology
| 3 anni |
| Henry Hoppe | M | - |
Massachusetts Institute of Technology
| 7 anni |
| Jerry L. Prince | M | - |
Massachusetts Institute of Technology
| 8 anni |
| Nicole P. Jones | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 1 anni |
| Wayne Frederick | M | 52 | 2 anni | |
| Mark Jennings | M | 63 |
Massachusetts Institute of Technology
| 5 anni |
| Michal Silverberg | F | 48 | 3 anni | |
| Donald Nicholson | M | 67 | 5 anni | |
| Tiffany Crowell | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Brian Eric Thompson | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Ruben Ojeda | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Patrick F. Kelly | M | 60 | 6 anni | |
| Karen Martin | M | - | 2 anni | |
| Sharon Townson | M | 49 | 1 anni | |
| Jocelyn E. Scott | F | - |
Massachusetts Institute of Technology
| 4 anni |
| Zaurie Zimmerman | F | - |
Massachusetts Institute of Technology
| 6 anni |
| Beth A. Marcus | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Timothy Clackson | M | 58 | 4 anni | |
| Marsha Fanucci | F | 70 | 8 anni | |
| James E. O'Neill | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Robert Tepper | M | 68 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 anni |
| Peter Wirth | M | 73 | 10 anni | |
| David Walt | M | 71 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 2 anni |
| Jan Hewlett | F | - |
Central Michigan University
| 8 anni |
| Brian Jacobs | M | 63 |
Massachusetts Institute of Technology
| 5 anni |
| Kei Yamamoto | F | - |
Massachusetts Institute of Technology
| 5 anni |
| John Robert Chisholm | M | - |
Massachusetts Institute of Technology
| 7 anni |
| Elizabeth Marie Robinson | M | - |
Massachusetts Institute of Technology
| 4 anni |
| William E. Nagengast | M | - |
Central Michigan University
| 5 anni |
| Anita Killian | F | - |
Massachusetts Institute of Technology
| 5 anni |
| Karen L. Roberts | F | 67 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 anni |
| John S. Langford | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Perry Ha | M | 62 |
Massachusetts Institute of Technology
| 6 anni |
| Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Brian E. Foody | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Brian Daniels | M | 65 |
Massachusetts Institute of Technology
| 4 anni |
| Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Peter Kolchinsky | M | 47 | 3 anni | |
| Yet-Ming Chiang | M | - |
Massachusetts Institute of Technology
| 8 anni |
| Gregg Burgess | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Jeff Russell | M | 67 |
Massachusetts Institute of Technology
| 4 anni |
| Albert Dyrness | M | 61 |
Massachusetts Institute of Technology
| 4 anni |
| John V. Guttag | M | 75 |
Massachusetts Institute of Technology
| - |
| David Goldfarb | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Daniel J. Kerkman | M | - |
Massachusetts Institute of Technology
| 3 anni |
| Michail M. Pankratov | M | - |
Massachusetts Institute of Technology
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Steve Hall
- Contatti personali